Skip to main content
Premium Trial:

Request an Annual Quote

Inverness Commences Tender Offer for Biosite Shares

NEW YORK (GenomeWeb News) — Inverness Medical Innovations today said it has commenced its tender offer to buy all of Biosite's outstanding shares at a price of $92.50 per share without interest.
 
Under the cash deal, Inverness would pay an additional $.015205 per share for each day after July 2 that the shares are not accepted for payment.
 
Inverness, which last week won a bidding war against Beckman Coulter to acquire Biosite, said Biosite's board has approved the sale.
 
Unless the tender offer is extended, Inverness said, it is set to expire at 12:00 midnight, EST, on June 25.
 
Inverness said after the deal closes Biosite will operate as a wholly owned Inverness subsidiary.

The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.